Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Separately, JPMorgan Chase & Co. set a $26.00 price objective on shares of Enanta Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $27.24.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.81% during mid-day trading on Tuesday, reaching $25.74. 144,615 shares of the company were exchanged. Enanta Pharmaceuticals has a 12 month low of $16.75 and a 12 month high of $41.77. The stock has a 50 day moving average price of $24.48 and a 200-day moving average price of $24.87. The stock has a market capitalization of $489.96 million, a P/E ratio of 17.02 and a beta of 0.52.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 8th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. Enanta Pharmaceuticals had a net margin of 32.59% and a return on equity of 11.31%. The firm had revenue of $14 million for the quarter, compared to analysts’ expectations of $13.07 million. During the same quarter last year, the company earned $0.13 earnings per share. The firm’s revenue was up 20.7% compared to the same quarter last year. Analysts predict that Enanta Pharmaceuticals will post $1.02 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in ENTA. Virginia Retirement System acquired a new position in shares of Enanta Pharmaceuticals during the first quarter worth approximately $540,000. Pacad Investment Ltd. boosted its position in shares of Enanta Pharmaceuticals by 15.3% in the first quarter. Pacad Investment Ltd. now owns 9,800 shares of the company’s stock worth $288,000 after buying an additional 1,300 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in shares of Enanta Pharmaceuticals by 53.2% in the first quarter. TIAA CREF Investment Management LLC now owns 88,848 shares of the company’s stock worth $2,609,000 after buying an additional 30,840 shares during the last quarter. Prudential Financial Inc. boosted its position in shares of Enanta Pharmaceuticals by 60.4% in the first quarter. Prudential Financial Inc. now owns 48,714 shares of the company’s stock worth $1,431,000 after buying an additional 18,344 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in shares of Enanta Pharmaceuticals by 2.9% in the first quarter. BlackRock Fund Advisors now owns 1,184,007 shares of the company’s stock worth $34,774,000 after buying an additional 33,777 shares during the last quarter. 70.82% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

5 Day Chart for NASDAQ:ENTA

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.